AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
79.02
+1.91 (2.47%)
May 21, 2024, 3:17 PM EDT - Market open
AstraZeneca Employees
AstraZeneca had 89,900 employees on December 31, 2023. The number of employees increased by 6,400 or 7.66% compared to the previous year.
Employees
89,900
Change (1Y)
6,400
Growth (1Y)
7.66%
Revenue / Employee
$529,600
Profits / Employee
$70,423
Market Cap
244.84B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
AZN News
- 10 hours ago - AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicines - CNBC
- 11 hours ago - AstraZeneca kicks off ‘new era of growth' with aim to hit $80 billion of sales by 2030 - Market Watch
- 13 hours ago - AstraZeneca aims to deliver $80 billion in total revenue by 2030 - Reuters
- 13 hours ago - AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 - Business Wire
- 1 day ago - AstraZeneca plans to build $1.5 bln manufacturing facility in Singapore - Reuters
- 1 day ago - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease - Business Wire
- 3 days ago - Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial - Reuters
- 5 days ago - AstraZeneca's investigational COVID drug meets primary goals in late-stage study - Reuters